0.19
+0.022(+13.14%)
Currency In USD
Address
2401 4th Avenue
Seattle, WA 98121
United States of America
Phone
206 838 0500
Sector
Healthcare
Industry
Biotechnology
Employees
40
First IPO Date
July 20, 2016
| Name | Title | Pay | Year Born |
| Mr. Marvin L. White | President, Chief Executive Officer & Director | 841,394 | 1962 |
| Ms. SoYoung Kwon J.D., LL.M. | Senior Vice President, General Counsel, Business Development & Corporate Affairs | 639,366 | 1969 |
| Mr. Jeffrey G. Lamothe CA | Executive Vice President & Chief Operating Officer | 722,511 | 1966 |
| Ms. Daphne L. Taylor | Senior Vice President & Chief Financial Officer | 0 | 1966 |
| Dr. Dirk Huebner M.D. | Chief Medical Officer | 0 | 1963 |
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndrome. The company's preclinical candidates also include ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers; and APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40. It also develoes APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.